The Department of Neurology, Semmelweis University, Budapest, Hungary is enrolling patients into the clinical trial investigating the prognostic value of biomarkers and the effect of tolperisone in acute low back pain and sciatic pain "BETA".
The main purpose of the trial is to identify biomarkers from the blood as well as electrophysiologic and morphometric features (chemical, electrophysiologic and ultrasound biomarkers) that reflect the intensity of pain and/or foretell the efficacy of pharmacological (non-surgical) treatment in patients with acute low back pain. The trial is designed to enroll male and female 18 to 80 years who are healthy pain-free volunteers (n=30) without pain or inflammation outside of the randomized study, to establish normal values of blood biomarkers.
Patients with acute (less than 1-month) low back pain with or without radicular signs, who do not have severe diseases (abscess, tumor, etc) in the background, already had CT or MRI scan during routine workup will also be included.
This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT05544656.